UPenn Says St. Jude Cancer Therapy Patent Is Invalid

Law360, New York (March 25, 2013, 7:54 PM EDT) -- The University of Pennsylvania on Friday sought to declare invalid a patent held by St. Jude Children’s Hospital related to a “groundbreaking” new immunotherapy treatment for cancer that is at the center of a pitched legal battle between the former collaborators.

The suit, launched in Pennsylvania federal court, is the third complaint filed by the parties in an ongoing dispute over the soured collaboration. Penn claims that the immunotherapy treatment in question was developed by university professor Carl H. June, though St. Jude was granted a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.